Effects of Low-Dose and Long-Term Treatment with Erythromycin on Interleukin-17 and Interleukin-23 in Peripheral Blood and Induced Sputum in Patients with Stable Chronic Obstructive Pulmonary Disease
Table 1
Patients and baseline characteristics.
Parameters
Control
Erythromycin
Group A
Group B
Patients,
18
18
18
Males, female,
16, 2
15, 3
17, 1
Age, years
69.3 ± 7.1
68.8 ± 6.0
67.3 ± 6.8
FEV1 (liters)
1.02 ± 0.41
1.04 ± 0.26
1.08 ± 0.26
FEV1 (% predicted)
42.1 ± 18.6
44.8 ± 13.9
46.5 ± 8.9
FEV1/FVC (%)
48.6 ± 8.4
47.4 ± 8.2
47.3 ± 3.8
FVC (liters)
2.5 ± 0.8
2.3 ± 0.6
2.4 ± 0.4
Smoking (pack-years)
41.1 ± 19.8
38.8 ± 28.6
43.9 ± 29.1
Body mass index (kg/m2)
23.2 ± 3.1
24.4 ± 3.0
23.1 ± 4.0
Current treatment, (%)
Inhaled corticosteroid
8 (44.4)
8 (44.4)
7 (38.9)
Theophylline
11 (61.1)
10 (55.6)
10 (55.6)
Inhaled anticholinergic
9 (50.0)
10 (55.6)
9 (50.0)
Inhaled 2-adrenergic agonists
13 (72.2)
12 (66.7)
12 (66.7)
The mean ± standard deviation is shown. No significant differences were observed between the 3 groups.
